Clinical trials: DME
Macular Edema, Diabetic Mellitus
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
The purpose of the study to assess the efficacy of pegaptanib sodium 0.3 mg comparing sham injection and to confirm safety of pegaptanib sodium 0.3 mg in subjects with diabetic macular edema.
- Conditions
- Macular Edema, Diabetic Mellitus, Retinal Disease
- Trial name
- NCT01100307
- Testing
- pegaptanib sodium
- Where
- 43 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Pfizer
Diabetic Macular Edema
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
- Trial name
- NCT02914613
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Diabetic Macular Edema
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to…
- Trial name
- RESTORE (NCT00687804)
- Testing
- Ranibizumab, Laser
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 345 people
- Sponsor
- Novartis
Diabetes Mellitus, Diabetic Macular Edema
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the…
- Trial name
- VIDI (NCT02302079)
- Testing
- ASP8232, ranibizumab
- Where
- 21 sites in United States
- Volunteers
- 96 people
- Sponsor
- Astellas Pharma Europe B.V.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
- Trial name
- DME (NCT05698329)
- Testing
- AIV007
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- AiViva BioPharma, Inc.
Diabetic Macular Edema
The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)
Observe the safety and tolerability of the single and multiple doses of 601 in DME patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple…
- Trial name
- NCT04151407
- Testing
- Drug 601
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with…
- Trial name
- NCT01997164
- Testing
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema (DME)
Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections daily for 28 days in patients with…
- Trial name
- NCT01702441
- Testing
- Subcutaneous AKB-9778
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aerpio Therapeutics
Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
- Trial name
- DME (NCT05802329)
- Testing
- OCU200
- Where
- 5 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ocugen
Diabetic Macular Edema
Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
To explore a more clinical feasible treatment regime with ranibizumab for DME to provide satisfactory treatment effect with a lower number of visits and injections.
- Trial name
- SALUTE-D (NCT02262260)
- Testing
- Labeled regime arm, Wait and Extend regime arm
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in…
- Trial name
- Pregonda (NCT06847854)
- Testing
- RO7497372
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 151 people
- Sponsor
- Genentech, Inc.
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- ATACAMA (NCT07841899)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema (DME)
A Study of Avoralstat In Participants With Diabetic Macular Edema
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
- Trial name
- NCT07228559
- Testing
- avoralstat
- Where
- 8 sites in United States, Australia
- Volunteers
- 3 people
- Sponsor
- BioCryst Pharmaceuticals
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 9 sites in United States
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Macular Edema
Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)
This study will assess the safety and tolerability of intravitreally (IVT) administered VEGF Trap-Eye in Japanese subjects with diabetic macular edema (DME) over the period of one year.
- Trial name
- VIVID-Japan (NCT01512966)
- Testing
- VEGF Trap-Eye (BAY86-5321)
- Where
- 18 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Bayer
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetic Macular Edema (DME)
Phase 4 IOP Signals Associated With ILUVIEN®
This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
- Trial name
- PALADIN (NCT02424019)
- Testing
- ILUVIEN 0.19 MG
- Where
- 41 sites in United States
- Volunteers
- 153 people
- Sponsor
- Alimera Sciences